Cancer Immunology, Immunotherapy

, Volume 55, Issue 10, pp 1209–1218 | Cite as

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells

  • Joseph W. Fay
  • A. Karolina Palucka
  • Sophie Paczesny
  • Madhav Dhodapkar
  • Dennis A. Johnston
  • Susan Burkeholder
  • Hideki Ueno
  • Jacques Banchereau
Original Article

Abstract

Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six vaccinations, one patient received five vaccinations, and six patients received four vaccinations. Peptide-specific immunity was measured by IFN-γ production and tetramer staining in blood mononuclear cells. The estimated median overall survival was 20 months (range: 2–83), and the median event-free survival was 7 months (range: 2–83). As of August 2005, four patients are alive (three patients had M1a disease and one patient had M1c disease). Three of them have had no additional therapy since trial completion; two of them had solitary lymph node metastasis, and one patient had liver metastasis. Patients who survived longer were those who mounted melanoma peptide-specific immunity to at least two melanoma peptides. The present results therefore justify the design of larger follow-up studies to assess the immunological and clinical outcomes in patients with metastatic melanoma vaccinated with peptide-pulsed CD34-derived DCs.

References

  1. 1.
    Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782–3793 PubMedGoogle Scholar
  2. 2.
    Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648PubMedGoogle Scholar
  3. 3.
    Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998–1012CrossRefPubMedGoogle Scholar
  4. 4.
    Balch C, Soong S, Thompson J (2004) The natural history of melanoma and factors predicting outcome. In: Thompson JF, Morton DL, Kroon BB (eds) Textbook of melanoma. Martin Dunitz, London and New York, pp 181–198Google Scholar
  5. 5.
    Lotze M, Dallal R, kirkwood J, Flickinger J (2001) Cutaneous melanoma. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. LWW, Philadelphia, pp 2012–2069Google Scholar
  6. 6.
    Davis ID, Jefford M, Parente P, Cebon J (2003) Rational approaches to human cancer immunotherapy. J Leukoc Biol 73:3–29CrossRefPubMedGoogle Scholar
  7. 7.
    Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR et al (1993) Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 11:1969–1977PubMedGoogle Scholar
  8. 8.
    Eggermont AMM, Gore M (2002) European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma. Semin Oncol 29(4):382–388CrossRefPubMedGoogle Scholar
  9. 9.
    Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS (2002) Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 20:2045–2052CrossRefPubMedGoogle Scholar
  10. 10.
    Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM (1999) Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 17:968–975PubMedGoogle Scholar
  11. 11.
    Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337–365CrossRefPubMedGoogle Scholar
  12. 12.
    Rosenberg SA (1997) Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18:175–182CrossRefPubMedGoogle Scholar
  13. 13.
    Urban JL, Schreiber H (1992) Tumor antigens. Annu Rev Immunol 10:617–644CrossRefPubMedGoogle Scholar
  14. 14.
    Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1–4CrossRefPubMedGoogle Scholar
  15. 15.
    Nagorsen D, Scheibenbogen C, Marincola FM, Letsch A, Keilholz U (2003) Natural T cell immunity against cancer. Clin Cancer Res 9:4296–4303PubMedGoogle Scholar
  16. 16.
    Klein G, Boon T (1993) Tumor immunology: present perspectives. Curr Opin Immunol 5:687–692CrossRefPubMedGoogle Scholar
  17. 17.
    Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P, Petersson M (1999) Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353–362CrossRefPubMedGoogle Scholar
  18. 18.
    Hirshaut Y, Slovin SF (1985) Harnessing T-lymphocytes for human cancer immunotherapy. Cancer 56:1366–1373PubMedCrossRefGoogle Scholar
  19. 19.
    Melief CJ, Kast WM (1991) T-cell immunotherapy of cancer. Res Immunol 142:425–429CrossRefPubMedGoogle Scholar
  20. 20.
    Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666–675CrossRefPubMedGoogle Scholar
  21. 21.
    Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3:630–641CrossRefPubMedGoogle Scholar
  22. 22.
    Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415–2432CrossRefPubMedGoogle Scholar
  23. 23.
    Pardoll DM (1998) Cancer vaccines. Nat Med 4:525–531CrossRefPubMedGoogle Scholar
  24. 24.
    Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11:263–270CrossRefPubMedGoogle Scholar
  25. 25.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854CrossRefPubMedGoogle Scholar
  26. 26.
    Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, Mackensen A (2003) Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol 170:2161–2169PubMedGoogle Scholar
  27. 27.
    Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 10;99(25):16168-16173Google Scholar
  28. 28.
    Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R et al (1992) Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 1993 Mar; 217(3):309]. Ann Surg 216:463–482Google Scholar
  29. 29.
    Morton DL, Hoon DS, Nizze JA, Foshag LJ, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK, Elashoff R (1993) Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 690:120–134PubMedCrossRefGoogle Scholar
  30. 30.
    Chan AD, Morton DL (1998) Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 25:611–622PubMedGoogle Scholar
  31. 31.
    Haigh PI, Difronzo LA, Gammon G, Morton DL (1999) Vaccine therapy for patients with melanoma discussion 1574 passim. Oncology (Huntingt) 13:1561–1574Google Scholar
  32. 32.
    Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL (1988) Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 61:1065–1070PubMedCrossRefGoogle Scholar
  33. 33.
    Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R (1992) Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157–1164PubMedCrossRefGoogle Scholar
  34. 34.
    Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271–296CrossRefPubMedGoogle Scholar
  35. 35.
    Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Ann Rev Immunol 18:767–811CrossRefGoogle Scholar
  36. 36.
    Starzl TE, Zinkernagel RM (1998) Antigen localization and migration in immunity and tolerance. N Engl J Med 339:1905–1913CrossRefPubMedGoogle Scholar
  37. 37.
    Zinkernagel RM (2003) On natural and artificial vaccinations. Annu Rev Immunol 21:515–546CrossRefPubMedGoogle Scholar
  38. 38.
    Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21:685–711CrossRefPubMedGoogle Scholar
  39. 39.
    Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138–147CrossRefPubMedGoogle Scholar
  40. 40.
    Steinman RM, Cohn ZA (1973) Identification of a novel cell type in peripheral lymphoid organs of mice I Morphology, quantitation, tissue distribution. J Exp Med 137:1142–1162CrossRefPubMedGoogle Scholar
  41. 41.
    Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83–93CrossRefPubMedGoogle Scholar
  42. 42.
    Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258–261CrossRefPubMedGoogle Scholar
  43. 43.
    Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109–1118CrossRefPubMedGoogle Scholar
  44. 44.
    Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N (2000) Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes [see comments]. J Clin Invest 105:R9–R14PubMedCrossRefGoogle Scholar
  45. 45.
    Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat Med 2:52–58CrossRefPubMedGoogle Scholar
  46. 46.
    Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332CrossRefPubMedGoogle Scholar
  47. 47.
    Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678CrossRefPubMedGoogle Scholar
  48. 48.
    Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517–1526CrossRefPubMedGoogle Scholar
  49. 49.
    Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458PubMedGoogle Scholar
  50. 50.
    Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, Ryback ME, Weber J (2001) Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24:66–78CrossRefPubMedGoogle Scholar
  51. 51.
    Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507–529CrossRefPubMedGoogle Scholar
  52. 52.
    Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G (2001) Dendritic cells as vectors for therapy. Cell 106:271–274CrossRefPubMedGoogle Scholar
  53. 53.
    Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, de Saint-Vis B, Jacquet C, Yoneda K, Imamura S, Schmitt D, Banchereau J (1996) CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 184:695–706CrossRefPubMedGoogle Scholar
  54. 54.
    Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M, Lanzavecchia A, Banchereau J (1997) CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 90:1458–1470PubMedGoogle Scholar
  55. 55.
    Shortman K, Liu YJ (2002) Mouse and human dendritic cell subtypes. Nature Rev Immunol 2:151–161CrossRefGoogle Scholar
  56. 56.
    Palucka AK, Dhodapkar MV, Paczesny S, Ueno H, Fay J, Banchereau J (2005) Boosting Vaccinations with Peptide-Pulsed CD34+ Progenitor-Derived Dendritic Cells Can Expand Long-Lived Melanoma Peptide-Specific CD8+ T Cells in Patients with Metastatic Melanoma. J Immunother 28:158–168CrossRefPubMedGoogle Scholar
  57. 57.
    Dhodapkar MV, Steinman RM, Sapp M, Desai H, Fossella C, Krasovsky J, Donahoe SM, Dunbar PR, Cerundolo V, Nixon DF, Bhardwaj N (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 104:173–180PubMedCrossRefGoogle Scholar
  58. 58.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  59. 59.
    Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  60. 60.
    Palucka AK, Dhodapkar MV, Paczesny S, Burkeholder S, Wittkowski KM, Steinman RM, Fay J, Banchereau J (2003) Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 26:432–439CrossRefPubMedGoogle Scholar
  61. 61.
    Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, Kirkwood JM, Scheibenbogen C, Schlom J, Maino VC, Lyerly HK, Lee PP, Storkus W, Marincola F, Worobec A, Atkins MB (2002) Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 25:97–138CrossRefPubMedGoogle Scholar
  62. 62.
    Masopust D, Vezys V, Marzo AL, Lefrancois L (2001) Preferential localization of effector memory cells in nonlymphoid tissue. Science 291:2413–2417CrossRefPubMedGoogle Scholar
  63. 63.
    Wang XZ, Stepp SE, Brehm MA, Chen HD, Selin LK, Welsh RM (2003) Virus-specific CD8 T cells in peripheral tissues are more resistant to apoptosis than those in lymphoid organs. Immunity 18:631–642CrossRefPubMedGoogle Scholar
  64. 64.
    Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A (2002) Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 94:805–818PubMedGoogle Scholar
  65. 65.
    Ueno H, Tcherepanova I, Reygrobellet O, Laughner E, Ventura C, Palucka AK, Banchereau J (2004) Dendritic cell subsets generated from CD34+ hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses. J Immunol Methods 285:171–180CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Joseph W. Fay
    • 1
  • A. Karolina Palucka
    • 1
  • Sophie Paczesny
    • 1
  • Madhav Dhodapkar
    • 2
    • 3
  • Dennis A. Johnston
    • 4
  • Susan Burkeholder
    • 1
  • Hideki Ueno
    • 1
  • Jacques Banchereau
    • 1
  1. 1.Baylor Institute for Immunology ResearchDallasUSA
  2. 2.The Rockefeller UniversityNew YorkUSA
  3. 3.Hematology ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Department of StatisticsBaylor UniversityWacoUSA

Personalised recommendations